QT Imaging (QTI) said Tuesday that the first routine inspection of its quality management system and related processes by the US Food and Drug Administration was completed with zero Form 483 observations.
The FDA inspector further provided positive feedback regarding the organization of QT Imaging's QMS and the its responsiveness throughout the inspection process, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments